Niva Bupa Health Insurance Company Limited (NSE:NIVABUPA)
India
· Delayed Price · Currency is INR | Market Cap | 142.25B |
| Revenue (ttm) | 79.67B |
| Net Income (ttm) | 2.92B |
| Shares Out | 1.85B |
| EPS (ttm) | 1.57 |
| PE Ratio | 49.00 |
| Forward PE | 83.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 903,315 |
| Average Volume | 798,097 |
| Open | 77.60 |
| Previous Close | 77.08 |
| Day's Range | 76.36 - 77.80 |
| 52-Week Range | 67.50 - 95.21 |
| Beta | n/a |
| RSI | 55.24 |
| Earnings Date | May 8, 2026 |
About NSE:NIVABUPA
Niva Bupa Health Insurance Company Limited provides health insurance products in India. It offers health insurance plans, such as individual, family, NRIs, senior citizens, personal accident, critical illness; travel insurance, including international and studying abroad insurance plans; and corporate insurance comprising group and start up health, group personal accident and OPD coverage, and group health insurance claim process. The company was formerly known as Max Bupa Health Insurance Company Limited and changed its name to Niva Bupa Healt... [Read more]
Financial Performance
In fiscal year 2025, NSE:NIVABUPA's revenue was 63.30 billion, an increase of 33.84% compared to the previous year's 47.30 billion. Earnings were 2.03 billion, an increase of 90.78%.
Financial StatementsNews
Niva Bupa Health Insurance Company Transcript: Q3 25/26
Nine-month PAT rose 74% year-over-year to INR 208 crore, with overall growth at 26% and retail at 33%. Q3 saw strong new business and digital channel growth, improved combined and expense ratios, and positive GST tailwinds. Industry initiatives and regulatory clarity support sustained performance.
Niva Bupa Health Insurance Company Transcript: Q2 25/26
H1 FY '26 saw 23% overall and 28% retail GWP growth, with PAT more than doubling year-over-year. GST reduction to 0% spurred over 50% retail growth in October, while combined and expense ratios improved. Group loss ratio rose due to mix, but retail remained stable.
Niva Bupa Health Insurance Company Transcript: Q1 25/26
Q1 saw 28% YoY growth (32% in retail), with IFRS PAT nearly doubling to INR 70 crore and combined ratio improving to 103.2%. Loss ratios rose due to reserve increases and group mix, but expense ratios improved; volume growth drove premium gains. Key industry initiatives and tech upgrades support future outlook.
Niva Bupa Health Insurance Company Transcript: Q4 24/25
GWP grew 32% like-for-like to INR 7,406 crores, with IFRS PAT up 21% to INR 203.3 crores. Retail market share rose, group business expanded, and medical inflation was contained at 5%. Solvency and expense ratios improved, with strong digital and distribution growth.
Niva Bupa Health Insurance Company Transcript: Q3 24/25
Q3 FY25 saw strong premium growth and improved profitability despite a major regulatory-driven accounting transition. Market share in retail health rose, technology adoption advanced, and expense ratios improved, with management confident in meeting future targets.
Niva Bupa Health Insurance Company Transcript: Q2 24/25
Gross and net premiums grew 36% year-over-year, with IFRS profit more than doubling and market share rising. Technology-driven operations, disciplined risk management, and strong digital channel growth underpin performance, while regulatory changes and seasonality remain key factors.